Clarke Charlotte H, Buckley Julie A, Fung Eric T
Ciphergen Biosystems, Inc., Diagnostic Division, Fremont, CA 94555, USA.
Clin Chem Lab Med. 2005;43(12):1314-20. doi: 10.1515/CCLM.2005.225.
The detection, diagnosis, and management of breast cancer rely on an integrated approach using clinical history, physical examination, imaging, and histopathology. The discovery and validation of novel biomarkers will aid the physician in more effectively achieving this integration. This review discusses efforts in surface-enhanced laser desorption/ionization (SELDI)-based proteomics to address various clinical questions surrounding breast cancer, including diagnosis, monitoring, and stratification for treatment. Emphasis is placed on examining how study design and execution influence the discovery and validation process, which is critical to the proper development of potential clinical tests.
乳腺癌的检测、诊断和管理依赖于一种综合方法，该方法运用临床病史、体格检查、影像学和组织病理学。新型生物标志物的发现和验证将有助于医生更有效地实现这种整合。本综述讨论了基于表面增强激光解吸/电离（SELDI）的蛋白质组学在解决围绕乳腺癌的各种临床问题方面所做的努力，包括诊断、监测和治疗分层。重点在于研究设计和实施如何影响发现和验证过程，这对潜在临床试验的正确开发至关重要。
